Abstract
An indigenous technology for the production of 125I brachytherapy sources has been developed for the management of intraocular cancer. This indigenous method of producing 125I seeds represents a new paradigm, and a thorough quality evaluation of the seeds in accordance with Atomic Energy Regulatory Board (AERB) of India was carried to ensure their safety during therapy. In this current work, we describe an overview of our experience, the efforts made in establishing enviable quality analysis of 125I seeds to ensure their safety in episcleral plaque brachytherapy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
